Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00891592 · ClinicalTrials.gov registry record · Phase 1
Umbilical Cord Blood Transplant for Hematological Malignancies
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00891592: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT00891592 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00891592, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This protocol will enroll subjects with advanced hematologic malignancies who do not have a suitable related or unrelated donor to undergo a Stem Cell Transplant. In this study, subjects will undergo a Stem Cell Transplant using Cord Blood. Part of the cord blood will be used for the Stem Cell Transplant and part of the cord blood will be sent to a laboratory in order to grow the T cells (from the cord blood) and increase the activity of the cord blood T cells. The purpose of this part of the study is to see if it is safe to give study subjects activated T cells made from a small portion of their donor UCB unit immediately after the UCB transplant. Activated T cells have been used safely in stem cell transplantation studies in the past, but they have never been studied UCB transplantation.
Interventions
- BIOLOGICAL Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells
- OTHER Observation Arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-01 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00891592
The ClinicalTrials.gov registry entry for NCT00891592 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells is the first listed.
NCT00891592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00891592 about?
NCT00891592 is a clinical study titled "Umbilical Cord Blood Transplant for Hematological Malignancies". This protocol will enroll subjects with advanced hematologic malignancies who do not have a suitable related or unrelated donor to undergo a Stem Cell Transplant. In this study, subjects will undergo a Stem Cell Transplant using Cord Blood. Part of the cord blood will be used for the Stem Cell Tran...
What is the current status of trial NCT00891592?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2009-01. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00891592?
The interventions under investigation include: Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells (BIOLOGICAL), Observation Arm (OTHER).
Who is sponsoring clinical trial NCT00891592?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.